Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment
NCT04118387Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of acetazolamide, zolpidem and buspirone in central sleep apnea (CSA) (3 arms), sponsored by VA Office of Research & Development. Primary endpoints: CO2 reserve at 120 days and Central apnea indices at 120 days. Started Jan 2021; status: recruiting.
02
Drugs
acetazolamidezolpidembuspirone
03
Conditions
central sleep apnea (CSA)
Beyond the preview
Go deeper on NCT04118387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118387.